Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.50−0.44 (-2.21%)
Close on Nov 18, 2026Market cap $5.51BP/E –Yield –
Caris Life Sciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Caris Life Sciences's revenue for the twelve months ending Sep 30, 2026 was $1.05B, up 61.5% year over year. For fiscal 2025 it was $812.03M, up 97.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $812.03M | +97.0% |
| FY2024 | Dec 31, 2024 | $412.26M | +34.7% |
| FY2023 | Dec 31, 2023 | $306.13M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $275.36M | +27.0% |
| Q2 FY2026 | Jun 30, 2026 | $263.71M | +45.4% |
| Q1 FY2026 | Mar 31, 2026 | $216.17M | +78.8% |
| Q4 FY2025 | Dec 31, 2025 | $292.89M | +125.4% |
| Q3 FY2025 | Sep 30, 2025 | $216.83M | +113.4% |
| Q2 FY2025 | Jun 30, 2025 | $181.40M | +81.3% |
| Q1 FY2025 | Mar 31, 2025 | $120.92M | – |
| Q4 FY2024 | Dec 31, 2024 | $129.92M | – |
| Q3 FY2024 | Sep 30, 2024 | $101.62M | – |
| Q2 FY2024 | Jun 30, 2024 | $100.05M | – |
See a number that looks wrong?